UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State ...

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects peak year XHANCE net revenues of at least $300 million from current specialist focused prescriber audience Company expects to produce positive income from operations (GAAP) for full year 2025 Conference call and webcast to be held today at 10:00 a.m. Eastern Time YARDLEY, Pa., May 14, 2024 Optinose (NASDAQ: ...

YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to st ...

YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to st ...

Corporate Presentation March 7, 2024 Forward-looking statements are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: impact of, and the uncertainties caused by, physician and patient acceptance of XHANCE for its current and any potential future indication; our ability to ...

OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Conference Call March 7, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Ramy Mahmoud - CEO Conference Call Participants Thomas Flaten - Lake Street David Amsellem - Piper Sandler Operator Good day, and thank you for standing by. Welcome to the OptiNose Fourth Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State of other jur ...

Exhibit 99.1 Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE's current nasal polyps indication and there is no FDA-approved medication for these patients Company reports fourth quarter and full yea ...

‒ Previously expected to be between $64 to $70 million -0.4 | --- | --- | --- | --- | --- | --- | --- | |---------|---------|---------|-------|--------------------------|--------|-----------------| | | | | | | | | | | | | | 0.0 | | | | N = 110 | N = 110 | N = 107 | | -0.2 | N = 75 | N = 72 N = 73 | | | | | | -0.4 | | | | | | | | -0.6 | | | | -0.62 | | | | -0.8 | | | | | | | | -1.0 | -0.81 | | | | | | | CSS Point Reduction -1.2 | | | | | | | | -1.4 | | | | | | | | -1.6 | | -1.54* | | | -1.58‡ | -1.60‡ | | | ...

OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Jonathan Neely - Vice President, Investor Relations and Business Development Dr. Ramy Mahmoud - Chief Executive Officer Paul Spence - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Operator Good day and thank you for standing by. Welcome to OptiNose Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the spe ...